29/01/2026
15:30 - 21:30 GMT
The Royal Society of Chemistry, Burlington House, Piccadilly, London, W1J 0BA
This event will offer attendees the rare opportunity to:
• Gain first-hand insight from global thought leaders driving AI policy and innovation.
• Discover how international collaboration can advance safe, ethical, and equitable AI use.
• Network with senior peers from across the regulatory, industry, and policy communities at one of London’s most
distinguished scientific venues.
Digital transformation is already reshaping how we diagnose, treat, and manage disease. AI systems are matching and sometimes surpassing human experts in diagnostic accuracy; they are streamlining clinical workflows and expanding access to care. Yet these breakthroughs also pose critical regulatory questions around transparency, public trust, data quality, and accountability. How can we enable innovation while protecting patient safety? Can we ensure that AI advances equitably across sectors, including human medicines, medical devices, and veterinary medicine? This lecture will cut to the heart of that challenge — and spark the collaboration needed to meet it.
Keynote Lecture

Dr Ricardo Baptista Leite, Chief Executive Officer at Health AI—The Global Agency for Responsible AI in Health, will deliver the keynote address: “Health AI: Championing Responsible AI in Healthcare”
Dr Baptista Leite leads Health AI, a global non-profit organisation that acts as an implementing partner for governments to build national regulatory capacities to promote equitable, safe, and effective AI adoption in health systems worldwide.
In his address, he will explore:
• The urgent need for harmonised global standards and capacity to ensure responsible AI in health
• Real-world examples of AI innovation and its emerging regulatory challenges
• How collaboration between health authorities, international agencies, and industry can drive responsible progress
• The future vision for ethical AI adoption across sectors
Following the keynote, Aman Khera, President of TOPRA, will chair a high-level discussion featuring:
• Dr Ricardo Baptista Leite, CEO, Health AI
• Lawrence Tallon, Chief Executive, MHRA
• Dr Ron Piervincenzi, Chief Executive, USP
• Dr Gabriella Spinelli, Associate Director of Innovation and Digital Health, Brunel
Together, they will explore how regulatory systems worldwide can collaborate to secure safe, effective, and transparent use of AI in healthcare, reflecting on progress to date and priorities for the years ahead.